Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
Generics businesses achieve pretty defendable margins, yet their valuations are at material discounts to most of the Big ...
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...
The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...
Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...
Three Motley Fool contributors believe they've identified healthcare stocks in the latter category. Here's why they think Eli Lilly (NYSE: LLY), Intuitive Surgical (NASDAQ: ISRG), and Vertex ...
Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
With every new year comes reflection and resolutions. But as we go to press well into January, it is worth a reminder that studies show nearly 90% ...
Eli Lilly and Company (NYSE:LLY) is a global leader in pharmaceuticals, offering treatments for diabetes, oncology, rheumatoid arthritis, psoriasis, migraines, and more. Its flagship products ...